Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Spyre Therapeutics (SYRE) EBITDA Margin: 2015-2023

Historic EBITDA Margin for Spyre Therapeutics (SYRE) over the last 5 years, with Jun 2023 value amounting to -23,146.22%.

  • Spyre Therapeutics' EBITDA Margin fell 1955854.00% to -23,146.22% in Q2 2023 from the same period last year, while for Jun 2023 it was -17,587.05%, marking a year-over-year decrease of 1709021.00%. This contributed to the annual value of -27,347.97% for FY2023, which is 2370774.00% down from last year.
  • As of Q2 2023, Spyre Therapeutics' EBITDA Margin stood at -23,146.22%, which was down 143.70% from -9,497.98% recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' EBITDA Margin registered a high of -55.88% during Q2 2021, and its lowest value of -23,146.22% during Q2 2023.
  • In the last 3 years, Spyre Therapeutics' EBITDA Margin had a median value of -3,587.68% in 2022 and averaged -6,777.45%.
  • Data for Spyre Therapeutics' EBITDA Margin shows a maximum YoY tumbled of 1,955,854bps (in 2023) over the last 5 years.
  • Over the past 3 years, Spyre Therapeutics' EBITDA Margin (Quarterly) stood at -560.98% in 2021, then crashed by 1,084,498bps to -11,405.95% in 2022, then tumbled by 1,955,854bps to -23,146.22% in 2023.
  • Its EBITDA Margin stands at -23,146.22% for Q2 2023, versus -9,497.98% for Q1 2023 and -11,405.95% for Q4 2022.